Table 1. Evaluating promoter and enhancer specificity to determine optimum transgenic construc configuration for enhancer characterization.

	β-globin (none)				γ-cry (eye)
	Transgenic Efficiency	Eye/Skin	Muscle/Kidney	Other	Transgenic Efficiency	Eye/Skin	Muscle/Kidney	Other
Promoter Only	0/173	0	0	0	43/56 (76%)	100%	0	0
IRX3 KE	27/101 (27%)	0	56%	44%	219/282 (77%)	60%	40%	0
Dystophin ME	97/202 (48%)	0	98%	2%	76/179 (42%)	47%	53%	0
MyoD ME	93/133 (70%)	0	100%	0	169/181 (93%)	4%	96%	0
	Irx3 (eye)				Krt8 (skin)
	Transgenic Efficiency	Eye/Skin	Muscle/Kidney	Other	Transgenic Efficiency	Eye/Skin	Muscle/Kidney	Other
Promoter Only	25/138 (18%)	60%	28%	22%	167/211 (79%)	80%	3%	17%
IRX3 KE	47/97 (48%)	30%	60%	10%	161/214 (75%)	60%	24%	16%
Dystophin ME	80/199 (40%)	2%	96%	2%	156/177 (88%)	25%	69%	6%
MyoD ME	87/173 (50%)	2%	98%	0	167/178 (93%)	9%	89%	2%
	Hsp68 (none)
	Transgenic Efficiency	Eye/Skin	Muscle/Kidney	Other
Promoter Only	86/110 (78%)	20%	56%	24%
IRX3 KE	79/99 (79%)	21%	49%	30%
Dystophin ME	162/182 (89%)	10%	75%	15%
MyoD ME	205/240 (85%)	12%	78%	10%